NCT02181218: Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas |
|
|
| Completed | 1 | 24 | US | Romidepsin, Istodax®, Gemcitabine, GEMZAR®, Oxaliplatin, Eloxatin TM, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Pegfilgrastim, Neulasta® | Washington University School of Medicine, Celgene | Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse | 03/19 | 06/20 | | |
